Desmopressin versus indomethacin treatment in primary nocturnal enuresis and the role of prostaglandins

What Was Tested

This controlled clinical trial paper looks at Vasopressin and Desmopressin.

Who Took Part

The abstract describes 25 patients taking part.

PubMed indexes the participants as children and teenagers.

Eighty-five children with primary nocturnal enuresis were followed up for a baseline period of 4 weeks, during which they recorded wet and dry nights.

After this period, the patients were divided into three groups that used desmopressin, indomethacin, or placebo for 4 weeks.

How the Study Was Run

In design terms this was a placebo-controlled study.

A placebo (an inactive look-alike) gave the Vasopressin group a baseline to be compared against.

A time span of 4 weeks appears in the methods.

The placebo group (group C) consisted of 25 patients.

The researchers determined the serum PGE2 and urine PGE2 concentrations before and after treatment in the three groups and in a control group.

What Was Measured

The subject headings attached to it are Deamino Arginine Vasopressin, Dinoprostone, Enuresis, Indomethacin and Renal Agents.

What This Means in Plain Language

The paper is a placebo-controlled study of Vasopressin and Desmopressin in 25 patients over 4 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1998 (Urology), a journal based in United States.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.